Search the Newsreel

Agenus advances Phase 3 ROBBIN trial of botensilimab-balstilimab in neoadjuvant MSS colon cancer

Agenus is moving forward with its Phase 3 ROBBIN trial for botensilimab and balstilimab in high-risk Stage II-III MSS colon cancer, with the first patient dosing expected in Q1 2027. This advancement follows positive results from earlier trials, NEST and UNICORN, which demonstrated significant …

NuScale Power Corporation (SMR) Reports Q2 Loss, Lags Revenue Estimates

NuScale Power Corporation (SMR) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.13 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it …

Supernus Pharmaceuticals Inc (SUPN) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth ...

Supernus Pharmaceuticals Inc (SUPN) reported strong revenue growth in Q2 2026, driven by key product sales and advancements in its late-stage pipeline. Despite competitive pressures and increased R&D expenses, the company reaffirmed its full-year financial guidance, projecting net revenue between $640 million and $660 …

NuScale Power (NYSE: SMR) Q2 2026 results show loss and $1.9B liquidity

NuScale Power (NYSE: SMR) reported a net loss of $47.5 million, or $0.13 per share, for Q2 2026, compared to a $17.6 million loss in the prior year, primarily due to higher R&D and G&A expenses. Revenue decreased significantly to $75 thousand from $8.0 …

Janus Living, Inc. 2Q 2026: Revenue $216.5M, EPS $0.05— 10-Q Summary

IPO and follow-on fuel Janus Living (NASDAQ: JAN) as it posts $14,858 Q2 profit

NuScale Power Reports Second Quarter 2026 Results

Second Quarter 2026 Highlights NuScale's exclusive global strategic partner, ENTRA1 Energy ("ENTRA1"), continues to advance discussions with the Tennessee Valley Authority ("TVA") toward a definitive power purchase agreement for potentially the largest nuclear power deployment program in U.S. history NuScale is working with S.N. …

JAN Stock Price and Chart — NYSE:JAN

This article provides an overview of Janus Living, Inc. (NYSE: JAN), a senior housing real estate investment trust. It details key financial statistics, including market capitalization, dividend yield, and recent earnings, highlighting significant revenue growth and raised guidance. The article also covers analyst ratings, …

Cooke & Bieler (JBI) discloses 5.10M Janus International shares in 13G/A

Cooke & Bieler L.P. filed an amended Schedule 13G/A, disclosing a beneficial ownership of 5,099,757 shares of Janus International Group, Inc. common stock, which represents 3.7% of the class. The firm reports shared voting power over 4,863,180 shares and shared dispositive power over all …

Press Release: Janus Living Reports Second Quarter 2026 Results and Increases Full Year 2026 Guidance

Janus Living announced its second quarter 2026 financial results, reporting strong performance that led to an increase in its full-year 2026 guidance. The company's positive financial trajectory indicates a successful first half of the year and confidence in continued growth. This updated outlook suggests …

Janus Living (NASDAQ: JAN) lifts 2026 guidance after Q2 revenue jumps 45%

Janus Living (NASDAQ: JAN) reported strong Q2 2026 results, with consolidated revenues up 45% year-over-year to $216 million and diluted EPS reaching $0.05. The company also announced significant portfolio expansion through acquisitions totaling $1.8 billion year-to-date and raised its full-year 2026 guidance for diluted …

NuScale Stock Decays After Q2 Revenues Miss Estimates - NuScale Power (NYSE:SMR)

Distribusi Voucher (DIVA) Mulai Alihkan Saham Buyback, Harga Saham Melejit

Cygnus Metals Advances CAML Takeover Scheme with Regulatory Milestones

Earnings Flash (JAN) Janus Living Posts Q2 Adjusted FFO $0.24, vs. FactSet Est of $0.25

Earnings Flash (JAN) Janus Living, Inc. Reports Q2 Revenue $216.5M, vs. FactSet Est of $215.2M

INDV to Merge With Supernus, Beats on Q2 Earnings, Raises '26 Outlook

Indivior Pharmaceuticals INDV has announced a definitive agreement to merge with Supernus Pharmaceuticals SUPN in a tax-free, all-stock merger of equals. The transaction will create a leading central nervous system (CNS)-focused biopharmaceutical company with a diversified portfolio of 11 marketed medicines spanning psychiatry, neurology …

Janus International Group (JBI) Expected to Release Quarterly Earnings on Tuesday

Janus International Group (JBI) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 11th. Analysts anticipate earnings of $0.13 per share and revenue around $238.8 million. The company's stock recently traded at $5.54, with institutional investors holding a significant …

Agenus Inc expected to post earnings of 5 cents a share - Earnings Preview

Agenus Inc is projected to report earnings of 5 cents per share. This information is presented as an earnings preview by Refinitiv, shared through TradingView News. The full article is available to subscribers of TradingView.

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form a diversified biopharmaceutical company focused on the central nervous system (CNS). The combined entity, which will operate under the name Supernus Inc. and trade on Nasdaq under 'SUPN', expects pro forma …

Earnings To Watch: NuScale Power Corp (SMR) Q2 2026 -- GF Value Sees 76% Upside

Supernus Pharmaceuticals (SUPN) Stock Rebounds As Revenue Growth Meets Profit Crunch

NuScale Power (SMR) Heads Into Earnings With Project Updates Putting Valuation Back In Focus

Here's What We Like About Venus Remedies' (NSE:VENUSREM) Upcoming Dividend

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for …

Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We …

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, …

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential securities claims against Agenus Inc. on behalf of investors who suffered losses exceeding $50,000 between January 23, 2023, and July 17, 2024. The investigation stems from allegations that Agenus made false or misleading statements regarding the effectiveness …

Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company

Supernus Pharmaceuticals and Indivior Pharmaceuticals are merging in an all-stock deal to form Supernus, Inc., a new CNS-focused pharmaceutical company. The combined entity will have a portfolio of 11 commercialized products across addiction, ADHD, depression, and Parkinson's disease, with nearly $2.2 billion in revenue. …

CNS-focused Supernus and Indivior agree merger terms

Supernus Pharma and Indivior have agreed to an all-stock merger, forming a new company, Supernus Inc., focused on CNS diseases with combined revenues of around $2.2 billion. The deal, expected to close in Q4, will see Indivior shareholders owning 56.5% of the new company …

Rockville's Supernus more than tripling size through merger of equals

Rockville's Supernus Pharmaceuticals is merging with Richmond-based Indivior in a "merger of equals" transaction. The combined company will be led by current Supernus CEO Jack Khattar and is expected to generate approximately $2.2 billion in annual revenue from nearly a dozen neurological and psychiatric …

Price to earnings forward of NuScale Power Corporation Class A – BX:SMR

This article provides financial information for NuScale Power Corporation Class A, traded under the symbol SMR on the BX Swiss exchange. It focuses on the company's price to earnings forward metric within the financial overview. The data and intellectual property are provided by various …

Supernus Q2 Falls To Loss, Despite 32% Revenue Jump; To Merge With Indivior In All-Stock Deal

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) Monday reported a slip to loss in the second quarter, on one-time impairment charges, interest expense and a reversal of income tax benefit to an expense, despite a 32% increase in revenue, compared to the prior year. The …

Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) for potential breaches of fiduciary duty related to its transaction with Indivior Pharmaceuticals. Supernus shareholders are set to receive 1.5401 common shares of Indivior for each Supernus share, resulting in Supernus stockholders owning approximately 43.5% …

Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics

Supernus Pharmaceuticals (SUPN) reported $219.06 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 32.4%. EPS of $0.54 for the same period compares to $0.91 a year ago. The reported revenue represents a surprise of +6.84% over the Zacks …